MCRB RSI Chart
Last 7 days
-2.5%
Last 30 days
-26.7%
Last 90 days
-39.4%
Trailing 12 Months
-85.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 0 | 132.1M | 131.2M | 127.8M |
2022 | 110.5M | 76.0M | 41.6M | 7.1M |
2021 | 30.7M | 30.0M | 155.3M | 144.9M |
2020 | 35.4M | 28.9M | 23.3M | 33.2M |
2019 | 31.6M | 39.5M | 37.5M | 34.5M |
2018 | 33.1M | 34.7M | 20.7M | 28.3M |
2017 | 22.1M | 22.1M | 32.1M | 32.1M |
2016 | 5.9M | 11.2M | 16.5M | 21.8M |
2015 | 0 | 0 | 0 | 638.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 16, 2024 | arkowitz david | sold | -4,254 | 1.08 | -3,939 | chief financial officer |
Feb 16, 2024 | shaff eric d. | sold | -12,472 | 1.08 | -11,549 | ceo and president |
Feb 16, 2024 | ege david s. | sold | -5,410 | 1.08 | -5,010 | see remarks |
Feb 16, 2024 | von moltke lisa | sold | -4,752 | 1.08 | -4,400 | see remarks |
Feb 16, 2024 | desrosier thomas | sold | -4,254 | 1.08 | -3,939 | chief legal officer and evp |
Feb 16, 2024 | young teresa l. | sold | -3,643 | 1.08 | -3,374 | see remarks |
Feb 16, 2024 | henn matthew r. | sold | -4,503 | 1.08 | -4,170 | see remarks |
Feb 15, 2024 | henn matthew r. | acquired | - | - | 11,250 | see remarks |
Feb 15, 2024 | shaff eric d. | acquired | - | - | 31,250 | ceo and president |
Feb 15, 2024 | young teresa l. | acquired | - | - | 10,625 | see remarks |
Which funds bought or sold MCRB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | reduced | -80.67 | -3,797 | 487 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 9.65 | -4,627,220 | 8,407,430 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 24.38 | -447,641 | 1,220,410 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.4 | -47,846 | 67,693 | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | added | 9.58 | -281,000 | 510,000 | -% |
Feb 15, 2024 | BARCLAYS PLC | reduced | -70.69 | -908,000 | 189,000 | -% |
Feb 15, 2024 | Legal & General Group Plc | reduced | -83.09 | -183,656 | 20,285 | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | added | 887 | 336,430 | 406,402 | -% |
Feb 15, 2024 | GTS SECURITIES LLC | sold off | -100 | -32,142 | - | -% |
Feb 15, 2024 | Virtus ETF Advisers LLC | sold off | -100 | -38,451 | - | -% |
Unveiling Seres Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Seres Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
Seres Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
Revenue | -79.4% | 64.00 | 310 | 126,473 | 975 | 3,444 | 1,216 | 4,219 | 7,221 | 126,725 | 5,263 | 5,718 | 17,564 | 1,417 | 6,045 | 8,189 | 7,622 | 7,031 | 12,531 | 7,321 | 10,629 | 9,055 |
Operating Expenses | -17.0% | 39,590 | 47,723 | 76,949 | 69,282 | 62,551 | 64,541 | 57,244 | 56,653 | 58,318 | 53,405 | 41,044 | 35,462 | 31,412 | 26,590 | 27,881 | 26,814 | 24,214 | 23,479 | 31,874 | 32,300 | 31,266 |
S&GA Expenses | -13.8% | 17,234 | 19,989 | 28,051 | 22,404 | 18,384 | 20,335 | 18,571 | 20,506 | 19,563 | 17,451 | 11,741 | 10,595 | 7,551 | 6,491 | 6,138 | 5,782 | 5,897 | 5,574 | 7,495 | 7,533 | 7,591 |
R&D Expenses | -5.0% | 26,846 | 28,253 | 46,792 | 46,220 | 43,116 | 43,935 | 39,649 | 36,752 | 39,882 | 35,954 | 29,303 | 24,867 | 23,861 | 20,099 | 21,743 | 21,032 | 18,317 | 17,905 | 22,887 | 24,767 | 23,675 |
Interest Expenses | 0.4% | 4,029 | 4,012 | 3,187 | 1,880 | 1,727 | 1,501 | 912 | 738 | 744 | 732 | 696 | 759 | 730 | 719 | 716 | - | - | - | - | - | 262 |
Net Income | 13.8% | -41,248 | -47,854 | 46,552 | -68,796 | -60,002 | -64,735 | -56,624 | -50,001 | 68,218 | -48,330 | -35,465 | -18,252 | -30,280 | -20,714 | -19,881 | -18,778 | -16,409 | -10,759 | -24,333 | -21,287 | -21,949 |
Net Income Margin | 17.4% | -0.89* | -1.08* | -2.30* | -35.09* | -5.56* | -1.36* | -0.79* | -0.45* | -0.22* | -4.42* | -3.41* | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | 20.8% | -48,376 | -61,052 | 64,751 | -56,353 | -60,829 | -52,060 | -69,395 | -53,441 | 123,650 | -42,249 | -30,838 | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -2.5% | 359 | 368 | 406 | 270 | 349 | 312 | 273 | 320 | 355 | 396 | 270 | 306 | 343 | 356 | 101 | 111 | 132 | 124 | 146 | 107 | 120 |
Current Assets | -18.2% | 175 | 214 | 251 | 116 | 195 | 248 | 210 | 263 | 304 | 359 | 225 | 252 | 269 | 308 | 73.00 | 81.00 | 100 | 90.00 | 109 | 68.00 | 93.00 |
Cash Equivalents | -19.9% | 136 | 170 | 230 | 95.00 | 163 | 214 | 135 | 161 | 188 | 227 | 74.00 | 67.00 | 116 | 207 | 62.00 | 55.00 | 65.00 | 49.00 | 102 | 54.00 | 86.00 |
Inventory | 60.0% | 30.00 | 19.00 | 5.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | -4.7% | 22.00 | 24.00 | 24.00 | 24.00 | 23.00 | 19.00 | 20.00 | 19.00 | 18.00 | 17.00 | 15.00 | 14.00 | 14.00 | 15.00 | 16.00 | 18.00 | 19.00 | 21.00 | 23.00 | 25.00 | 26.00 |
Liabilities | 5.4% | 403 | 383 | 384 | 318 | 338 | 244 | 250 | 239 | 223 | 221 | 169 | 162 | 168 | 168 | 166 | 172 | 181 | 156 | 164 | 177 | 169 |
Current Liabilities | 24.5% | 99.00 | 79.00 | 78.00 | 64.00 | 86.00 | 82.00 | 89.00 | 82.00 | 82.00 | 95.00 | 56.00 | 48.00 | 46.00 | 46.00 | 44.00 | 44.00 | 46.00 | 42.00 | 43.00 | 42.00 | 42.00 |
Shareholder's Equity | -Infinity% | -44.86 | - | 23.00 | - | 11.00 | 68.00 | 23.00 | 81.00 | 132 | 176 | 101 | 144 | 175 | 188 | - | - | - | - | - | - | - |
Retained Earnings | -4.4% | -978 | -936 | -889 | -935 | -864 | -795 | -735 | -670 | -614 | -564 | -632 | -584 | -548 | -530 | -500 | -479 | -459 | -440 | -424 | -413 | -389 |
Additional Paid-In Capital | 1.2% | 933 | 922 | 912 | 888 | 875 | 863 | 759 | 752 | 746 | 740 | 734 | 728 | 723 | 718 | 435 | 418 | 411 | 409 | 406 | 344 | 341 |
Shares Outstanding | 5.0% | 135 | 129 | 128 | 127 | 125 | 123 | 92.00 | 92.00 | 92.00 | 92.00 | 92.00 | 92.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | - | 240 | - | - | - | 1,645 | - | - | - | 220 | - | - | - | 132 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 19.8% | -47,499 | -59,255 | 65,984 | -76,584 | -52,892 | -59,582 | -49,897 | -66,445 | -51,863 | 127,742 | -39,695 | -29,496 | -17,927 | -25,866 | -25,566 | -24,251 | -14,047 | -18,292 | -11,788 | -32,393 | 12,666 |
Share Based Compensation | -41.4% | 5,086 | 8,673 | 13,492 | 6,850 | 7,291 | 6,364 | 6,748 | 5,079 | 5,674 | 5,846 | 5,078 | 3,624 | 2,702 | 2,249 | 1,914 | 1,959 | 2,145 | 2,037 | 2,097 | 2,065 | 3,754 |
Cashflow From Investing | 51.2% | -877 | -1,797 | 10,517 | 2,739 | 5,926 | 40,131 | 23,399 | 12,972 | 13,186 | 25,112 | 46,528 | -20,738 | -75,335 | -110,644 | 17,651 | 9,437 | 4,653 | -34,524 | -341 | -306 | 17,396 |
Cashflow From Financing | 345.5% | 6,429 | 1,443 | 58,177 | 5,656 | 4,597 | 98,027 | 130 | 26,848 | -780 | 609 | 585 | 764 | 1,985 | 282,300 | 14,594 | 4,545 | 25,110 | -118 | 60,759 | 480 | 45.00 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenue: | |||
Collaboration revenue - related party | $ 126,325 | $ 7,128 | $ 143,857 |
Type of Revenue [Extensible List] | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember |
Grant revenue | $ 0 | $ 0 | $ 1,070 |
Total revenue | 126,325 | 7,128 | 144,927 |
Operating expenses: | |||
Research and development expenses | 145,860 | 172,920 | 141,891 |
General and administrative expenses | 87,744 | 79,694 | 69,261 |
Collaboration (profit) loss sharing - related party | 704 | 1,004 | (1,732) |
Total operating expenses | 234,308 | 253,618 | 209,420 |
Loss from operations | (107,983) | (246,490) | (64,493) |
Other (expense) income: | |||
Interest income | 7,301 | 3,058 | 2,870 |
Interest expense | (13,176) | (6,020) | (2,910) |
Other income (expense) | 134 | (705) | (1,045) |
Total other (expense) income, net | (5,741) | (3,667) | (1,085) |
Net loss | $ (113,724) | $ (250,157) | $ (65,578) |
Net loss per share attributable to common stockholders, basic | $ (0.89) | $ (2.31) | $ (0.72) |
Net loss per share attributable to common stockholders, diluted | $ (0.89) | $ (2.31) | $ (0.72) |
Weighted average common shares outstanding, basic | 128,003,294 | 108,077,043 | 91,702,866 |
Weighted average common shares outstanding, diluted | 128,003,294 | 108,077,043 | 91,702,866 |
Other comprehensive income (loss): | |||
Unrealized gain (loss) on investments, net of tax of $0 | $ 10 | $ 49 | $ (12) |
Currency translation adjustment | 2 | (1) | (1) |
Total other comprehensive income (loss) | 12 | 48 | (13) |
Comprehensive loss | $ (113,712) | $ (250,109) | $ (65,591) |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | ||||
---|---|---|---|---|---|---|
Current assets: | ||||||
Cash and cash equivalents | $ 127,965 | $ 163,030 | ||||
Short term investments | 0 | 18,311 | ||||
Collaboration receivable - related party | 8,674 | 0 | ||||
Inventories | 29,647 | 0 | ||||
Prepaid expenses and other current assets | 9,124 | 13,423 | ||||
Total current assets | 175,410 | 194,764 | ||||
Property and equipment, net | 22,457 | 22,985 | ||||
Operating lease assets | 109,793 | 110,984 | ||||
Restricted cash | 8,185 | 8,185 | ||||
Restricted investments | 1,401 | 1,401 | ||||
Other non-current assets | [1] | 41,354 | 10,465 | |||
Total assets | 358,600 | 348,784 | ||||
Current liabilities: | ||||||
Accounts payable | 3,641 | 17,440 | ||||
Accrued expenses and other current liabilities | [2] | 80,611 | 59,840 | |||
Operating lease liabilities | 6,677 | 3,601 | ||||
Short term portion of note payable, net of discount | 0 | 456 | ||||
Deferred income - related party | 7,730 | 0 | ||||
Deferred revenue - related party | 0 | 4,259 | ||||
Total current liabilities | 98,659 | 85,596 | ||||
Long term portion of note payable, net of discount | 101,544 | 50,591 | ||||
Operating lease liabilities, net of current portion | 105,715 | 107,942 | ||||
Deferred revenue, net of current portion - related party | 95,364 | 92,430 | ||||
Warrant liability | 546 | 0 | ||||
Other long-term liabilities | 1,628 | 1,442 | ||||
Total liabilities | 403,456 | 338,001 | ||||
Commitments and contingencies (Note 16) | ||||||
Stockholders (deficit) equity: | ||||||
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022 | 0 | 0 | ||||
Common stock, $0.001 par value; 240,000,000 and 200,000,000 shares authorized at December 31, 2023 and 2022, respectively; 135,041,467 and 125,222,273 shares issued and outstanding at December 31, 2023 and 2022, respectively | 135 | 125 | ||||
Additional paid-in capital | 933,244 | 875,181 | ||||
Accumulated other comprehensive loss | 0 | (12) | ||||
Accumulated deficit | (978,235) | (864,511) | ||||
Total stockholders' (deficit) equity | (44,856) | 10,783 | ||||
Total liabilities and stockholders' equity | $ 358,600 | $ 348,784 | ||||
|